設爲首頁|加入收藏|英文版

總體介紹

首頁 > 廣東省中醫藥科學院 > 總體介紹

中醫藥防治乳腺病研究團隊

2017/7/18 9:52:28字號:T|T

 

中醫藥防治乳腺病研究團隊是在复兴中华医学的战略背景下,作为我院國家中醫藥管理局乳腺病重点建设专科的组成部分于2015年正式成立。團隊充分結合中醫藥基礎理論與現代分子醫學體系,針對臨床乳腺病學的難點和盲區進行探索性研究,以有效、客觀和科學爲宗旨,積極推進中醫與西醫、臨床與基礎、理論與産品之間的轉化研究。主要目標是探討乳腺癌應激生物行爲學的調節機制和及相關靶點,並以此闡釋中醫治療乳腺癌的理論和實踐基礎,篩選靶向應激的小分子調節劑,力爭在中西醫結合領域形成理論創新、技術創新、方法創新的研究成果。

With the overwhelming trend of developing traditional Chinese Medicine (TCM) worldwide, the integrative research laboratory of breast diseases prevention & treatment was established in 2015. As an important part of the key specialist construction project supported by SATCM (state administration of TCM), our laboratory aims to integrate TCM and modern molecular medicine pointing at the clinical difficult problems (cancer drug resistance, metastasis, prevention, etc), and to carry out translational study between TCM and western medicine, between clinical and basic research and between theory discovery and product commercialization with the criteria of efficacy, safety and high scientific value. The main research focus is to explore the stress-related signaling in breast cancer development, identify the potential therapeutic targets and screen bioactive stress modulating drugs from TCM. Our research will not only provide theoretical and laboratory evidence for integrative cancer treatment, but also generate creative technology & methodology for TCM research.

 

團隊成員  Team Members

學術帶頭人Academic leaders



   林毅,主任医师,教授,廣州中醫藥大學主任导师。全国名中医,廣州中醫藥大學附属廣東省中醫院一级教授,全国第二批、第四批继承老中医药专家学术经验指导老师,國家中醫藥管理局全國名老中醫傳承工作室名師,國家中醫藥管理局乳腺病重點專科學科帶頭人,從事中醫、中西醫結合乳腺病臨床、教學和科研工作50余年,研究內環境因素對乳腺病發生發展的影響及機制,在全國具有鮮明的學術特點和重要的學術地位。  

Professor Lin Yi, chief physician, first-class professor in Guangzhou University of Chinese Medicine, national famous TCM expert, academic leader of state mammary diseases specialists. She devotes into breast research more than 50 years and has rich experience in dealing mammary inflammation, hyperplasia and breast cancer, etc. During her career life, she was awarded national health advanced worker twice and one national patent. Her main research focus on discovering novel factors influencing breast disease occurrence and prognosis from a unique perspective of internal environment.

 團隊負責人 Principle Investigator:

王志宇,博士,研究员,中醫藥防治乳腺病研究團隊負責人。主攻应激因素与乳腺癌发生发展及中医药防治。担任中华中医药学会乳腺病分会及广东省中医药学会乳腺病专业委员会委員,世界中醫藥學會聯合會中藥系統與工程分會常務理事。主持國家自然科學基金2項,廣東省自然科學基金傑出青年項目1項,廣州市珠江科技新星1項,香港衛生署基金項目等課題6項,經費300余萬元,發表SCI論文30余篇,累積影響因子100余點,擔任多種國際雜志編委及審稿專家。

Professor Wang Zhiyu, Ph.D, M.D., Principle investigator. His main research focuses on identification and characterization of stress-related targets in breast cancer development and TCM intervention. He served as a committee member of TCM science& technology committee affiliated to world federation of Chinese Medicine societies and mammary disease committee of Guangdong TCM association, etc. He successfully applied 6 grants including two NSFC projects, one Guangdong Natural Science Fund for Distinguished Scholar, one Pearl River Nova Program of Guangzhou, and one Hong Kong HMRF project, etc. The total funds reached over 3 million. He published over 30 articles indexed by SCI with a total impact factor over 100 points. Meanwhile, He served as editorial member or reviewer for a variety of peer-reviewed international journals.

客座教授及團隊骨幹  Team Core Members

客座教授

 

 

陳建萍 教授

香港大學

中醫藥防治乳腺癌的中西醫結合轉化研究

沈剑刚 教授

香港大學

腫瘤靶點鑒定及生物行爲學研究

张奉学 教授

廣州中醫藥大學

腫瘤免疫治療與中醫藥防治轉化研究

唐海林 副教授

中山大學

乳腺癌靶向治療

王能   副教授

廣州中醫藥大學

中草藥抗腫瘤藥理及分子靶點鑒定方法學研究;

王迪   副教授

吉林大學

中草藥抗腫瘤藥理及分子靶點鑒定方法學研究;

高磊   副教授

南方醫科大學

腫瘤靶點鑒定及生物行爲學研究

團隊骨幹

 

 

鄧海霞 博士

中醫藥防治乳腺病研究團隊

中醫藥防治乳腺癌的中西醫結合轉化研究

郑轶枫 博士

中醫藥防治乳腺病研究團隊

腫瘤應激調控機制及靶標分子的鑒定

王胜奇 博士

中醫藥防治乳腺病研究團隊

腫瘤應激調控機制及靶標分子的鑒定




團隊主攻方向 Main Research Direction

(1) 腫瘤應激調控機制及靶標分子的鑒定;

Stress-related Mechanisms and Therapeutic Targets Involved in Cancer Development

腫瘤在從惡性轉化到耐藥轉移的發展過程中,不斷接受內源性和外源性的各種應激刺激,如代謝應激、氧化應激、內質網應激等等,正是應激性因素驅動了腫瘤的進化,鑒定並發現應激調控保護分子機制及靶向藥物將會爲有效幹預腫瘤發生與轉移提供特異而高效的突破口,爲改善腫瘤預後提供新思路;


 

During the process from malignant transformation to advanced cancer drug resistance or metastasis, cancer cells have to adapt to multiple stress signal stimulus such as metabolism alteration, redox pressure and endoplasmic reticulum stress, etc. It is considered that stress signal might be the root for cancer evolution. Therefore, identification and characterization of stress-related mechanisms and targeting drugs will shed novel light for preventing cancer initiation and metastasis.  

 

(2)中草藥抗腫瘤藥理及分子靶點鑒定方法學研究;

Pharmacological Mechanisms of Anti-cancer Herbs and Development of Novel Target Identification System

中藥由于藥效成分複雜、分子機制不清,國際推廣受到很大阻力,而傳統的藥效成份分析分離技術耗時耗力,急需開發新型技術鑒定藥效成分及分子靶標。基于生物組學技術的發展,團隊擬開發基于靶標蛋白與小分子化合物結合穩定性的磁力共沈澱技術構建新型藥效成份鑒定系統。同時期望構建多靶點聚合芯片,采用分子動力學技術檢測小分子化合物的直接靶標蛋白,提速中醫藥現代化、國際化進程;

   Due to the complex ingredients, unclear molecular mechanisms and the traditional time-consuming separation technique, the internalization of TCM faces a big challenge, it is necessary and urgent to develop novel techniques in identifying bioactive compounds and their molecular targets. With the development of omics study, our team has developed a target identification system based on drug-target affinity response to protease degradation. Meanwhile, we aim to establish a target-based chip to identify the potential phytochemical inhibitor from Chinese herbs by SPR technology. We believe the development of hi-technology of target identification will promote the modernization of TCM. 


(3) 中醫藥防治乳腺癌的中西醫結合轉化研究;

Translational Breast Cancer Research of Integrative Medicine

    中醫藥在腫瘤預防、改善腫瘤預後、減毒增效及提高生存質量方面具有鮮明特色,但面臨標准不一、機制不清、臨床證據不足等問題,從中醫藥系統循證評價、質量標准統一、臨床前藥效藥理研究、毒理研究、臨床試驗及二次優化開發等角度進行中西醫結合研究將爲中醫藥臨床精准幹預乳腺癌防治提供有力證明;

TCM has a unique priority on cancer prevention, survival prolongation, detoxification and life quality improvement, but there exist huge difficulties in criteria standardization, mechanism clarification and large-scale clinical trials. It is necessary to promote integrative study from the perspectives of meta-analysis, chemical quality standardization, pre-clinical efficacy and toxicity study, clinical trial and secondary optimizing research, the results will provide convincing evidence for TCM precise intervention in clinical settings.  
 
 

主要學術及研究成果                       



 承擔的主要研究課題:

 

課題名稱

任務來源

級別

負責人

經費

(萬元)

Caveolin-1介導乳腺癌幹細胞化療抵抗和幹性維持的作用和分子機制

國家自然科學基金委員會

國家級

王志宇

23

基于腫瘤幹細胞免疫微環境TAMs/CXCL-1通路探討消癖顆粒預防乳腺癌的分子機制和物質基礎

國家自然科學基金委員會

國家級

王志宇

74

Caveolin-1抑制腫瘤幹細胞Warburg效應對乳腺癌的預防作用及分子機制研究

珠江科技新星

省部級

王志宇

60

內質網應激蛋白GRP78介導乳腺癌幹細胞化療抵抗的作用機制及其小分子抑制劑異甘草素的開發研究

廣東省傑出青年基金

省部級

王志宇

100

基于腫瘤幹細胞代謝特征探討消癖顆粒調控Caveolin-1預防乳腺癌的分子機制和物質基礎

高水平大學建設項目

院校級

王志宇

20

Exploration of dietary compound isoliquiritigenin in chemosensitizing  breast cancer stem cells by targeting aberrant β-catenin signalling 

香港衛生署

國際級

王志宇

 

75.836

基于“內環境平衡”探索中醫藥幹預乳腺癌的研究

廣東省中醫藥局

省部級

林毅

50

林毅名醫工作室建設項目

國家中醫藥管理局

 省部級

司徒紅林

50

基于“邪之所湊,其氣必虛”探討乳腺癌轉移前VEGFR1+HP

變化及複康靈膠囊對其影響

廣東省中醫院院内专项

省部級

陳前軍

25


发表的主要学术論文:

 

論文

期刊

影響

因子

第一

作者

通訊作者

The inflammasome: an emerging therapeutic target for cancer prevention

Oncotarget, 2016

5.008

王志宇

王志宇

Broadleaf Mahonia attenuates granulomatous lobular mastitis-associated inflammation by inhibiting CCL-5 expression in macrophages

International Jouranl of Molecular Medicine, 2017

2.348

王志宇

王志宇

Caveolin-1, a stress-related oncotarget, in drug ressitance

Oncotarget, 2015

6.359

王志宇

王志宇

Targeting AMPK signaling pathway to overcome drug resistance for cancer therapy

Current Drug Targets, 2015

3.597

王志宇

王志宇

Dietary Compound Isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF-1 demethylation

Oncotarget, 2015

 

6.359

王志宇

陳建萍

Caveolin-1 mediates chemoresistance of breast cancer stem cells via β-catenin/ABCG2 signaling pathway

Carcinogenesis, 2014

5.266

王志宇

陳建萍

MicroRNA-25 regulates autophagy associated with chemoresistance of breast cancer cells: a process modulated by natural autophagy inducer isoliquiritigenin

Oncotarget, 2014

6.627

王志宇

陳建萍

Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling

Carcinogenesis, 2014

5.266

王志宇

陳建萍

Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells

Oncogene, 2010

7.414

鄧海霞

宋爾衛


Contact information:

Tel: +86-18819480766;

Email: wangzhiyu@gzucm.edu.cn; wangzhiyu976@126.com;

分享到:新浪微博騰訊微博豆瓣人人網
首頁|網站地圖|法律申明|友情鏈接|招聘信息|供應商管理|名老中醫學術交流|中醫健康管理|中醫醫案管理 |知識管理|在線考試